Maryam Lustberg B MD, MPH

Maryam Lustberg B MD, MPH
Asst ProfessorCollege of Medicinelustberg.3@osu.edu
B421 Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:614-366-8541Fax: (614) 293-7529
  • Cancer Control

Research Description

Dr. Lustberg's research focus is on novel biomarkers in experimental therapeutics. She has ongoing research protocol with blood based markers including circulating tumor cells and microvesicles.

Current Publications

  • Pachman DR, Watson JC, Lustberg MB, Wagner-Johnston ND, Chan A, Broadfield L, Cheung YT, Steer C, Storey DJ, Chandwani KD, Paice J, Jean-Pierre P, Oh J, Kamath J, Fallon M, Strik H, Koeppen S, Loprinzi CLManagement options for established chemotherapy-induced peripheral neuropathy.Support Care Cancer 22 2281-95 8/1/2014
  • Mrózek E, Layman R, Ramaswamy B, Lustberg M, Vecchione A, Knopp MV, Shapiro CLPhase II Trial of Neoadjuvant Weekly Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Biweekly Bevacizumab Therapy in Women With Clinical Stage II or III HER2-Negative Breast Cancer.Clin Breast Cancer 14 228-34 8/1/2014
  • Wagner-Johnston N, Bak K, Loprinzi CL, American Society of Clinical Oncology, Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep SPrevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: american society of clinical oncology clinical practice guideline.J Clin Oncol 32 1941-67 6/20/2014
  • Puhalla S, Shapiro CL, Ramaswamy B, Zhao M, Pan X, Layman R, Lustberg MB, Mrozek E, Macrae ER, Wesolowski R, Carothers SA Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer.Invest New Drugs in press 6/5/2014
  • Wesolowski R, Abdel-Rasoul M, Lustberg M, Paskell M, Shapiro CL, Macrae ERTreatment-related mortality with everolimus in cancer patients.Oncologist 19 661-8 6/1/2014
  • Wu Y, Deighan CJ, Miller BL, Balasubramanian P, Lustberg MB, Zborowski M, Chalmers JJIsolation and analysis of rare cells in the blood of cancer patients using a negative depletion methodology.Methods 64 169-82 12/1/2013
  • Abandeh FI, Lustberg M, Devine S, Elder P, Andritsos L, Martin SIOutcomes of hematopoietic SCT recipients with rhinovirus infection: a matched, case-control study.Bone Marrow Transplant 48 1554-7 11/1/2013
  • Aggarwal R, Lu J, Kanji S, Das M, Joseph M, Lustberg MB, Ray A, Pompili VJ, Shapiro CL, Das HHuman Vγ2Vδ2 T cells limit breast cancer growth by modulating cell survival-, apoptosis-related molecules and microenvironment in tumors.Int J Cancer 133 2133-44 11/1/2013
  • Poi MJ, Berger M, Lustberg M, Layman R, Shapiro CL, Ramaswamy B, Mrozek E, Olson E, Wesolowski RDocetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review.Support Care Cancer 21 2679-86 10/1/2013
  • Wenzell CM, Berger MJ, Blazer MA, Crawford BS, Griffith NL, Wesolowski R, Lustberg MB, Phillips GS, Ramaswamy B, Mrozek E, Layman RM, Flynn JM, Shapiro CLPilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy.Support Care Cancer 21 2845-51 10/1/2013
  • Lynn M, Mrozek E, Ramaswamy B, Lustberg MB, Wesolowski R, Ottman S, Carothers S, Bingman A, Reinbolt R, Kraut EH, Shapiro CL, Layman RM, Ruppert ASSevere and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer.Cancer Chemother Pharmacol 71 1183-90 5/1/2013
  • Lustberg MBManagement of neutropenia in cancer patients.Clin Adv Hematol Oncol 10 825-6 12/1/2012
  • Lustberg MB, Reinbolt RE, Shapiro CLBone health in adult cancer survivorship.J Clin Oncol 30 3665-74 10/20/2012
  • Sammet C, Shapiro C, Knopp MV, Yang X, Mrozek E, Lustberg M, Jia G, Sammet SMicrocirculatory fraction (MCF(I)) as a potential imaging marker for tumor heterogeneity in breast cancer.Magn Reson Imaging 30 1059-67 10/1/2012
  • Berger MJ, Dunlea LJ, Rettig AE, Lustberg MB, Phillips GS, Shapiro CLFeasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.Support Care Cancer 20 1991-7 9/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu